US20040105854A1 - Antibodies active against a fusion polypeptide comprising a histidine portion - Google Patents

Antibodies active against a fusion polypeptide comprising a histidine portion Download PDF

Info

Publication number
US20040105854A1
US20040105854A1 US10/686,355 US68635503A US2004105854A1 US 20040105854 A1 US20040105854 A1 US 20040105854A1 US 68635503 A US68635503 A US 68635503A US 2004105854 A1 US2004105854 A1 US 2004105854A1
Authority
US
United States
Prior art keywords
histidine
fusion polypeptide
antibodies
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/686,355
Inventor
Hanswalter Zentgraf
Claudia Tessmer
Iris Velhagen
Susanne Schwinn
Manfred Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7755368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040105854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to US10/686,355 priority Critical patent/US20040105854A1/en
Publication of US20040105854A1 publication Critical patent/US20040105854A1/en
Priority to US12/465,855 priority patent/US7713712B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24

Definitions

  • the present invention relates to antibodies which are active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and their use.
  • the above column is expensive. Furthermore, its use costs a lot of time. Therefore, it is not suited for the rapid detection of the expression of a histidine fusion polypeptide. But such a detection is necessary, particularly when it shall be used for screening many cells.
  • Such an antibody may be a polyclonal or monoclonal antibody, a monoclonal antibody being preferred.
  • the antibody may be obtained from any animal or human being, rabbits being preferred for a polyclonal antibody and mice being preferred for a monoclonal antibody.
  • the antibody may be synthetic, portions which are not necessary for the above-mentioned identification optionally lacking fully or partially therefrom and these portions being replaced by others which give the antibody further favorable properties, respectively.
  • fusion polypeptide comprising a histidine portion comprises a polypeptide (peptide) of any kind and length which has a histidine portion.
  • a polypeptide may be expressed by any cells, e.g. bacteria, yeasts, cells of insects, plants and animals, as well as organisms, e.g. transgenic animals.
  • An above histidine portion may comprise e.g. 6-18, preferably 6, successive histidine residues and be fused to the N and/or C terminus of the polypeptide.
  • a preferred antibody of the present invention namely a monoclonal mouse antibody having the above identification, was deposited under No. ACC 2207 with the DSM [German-type collection of microorganisms] on Feb. 15, 1995.
  • Antibodies according to the invention can be prepared according to conventional methods. If polyclonal antibodies and monoclonal antibodies, respectively, are to be prepared, it will be favorable to immunize animals, particularly rabbits for the former antibodies and mice for the latter antibodies, with an above histidine fusion polypeptide e.g. His p53 (cf. German patent application P 42 32 823.3) or His hdm2 (cf. German patent application P 43 39 553.3), preferably a mixture thereof. The animals can be further boostered with the same histidine fusion polypeptide or polypeptides. Other histidine fusion polypeptides or a combination of these and the preceding histidine fusion polypeptide or polypeptides may also be used for boostering. The polyclonal antibodies may then be obtained from the serum of the animals. Spleen cells of the animals are fused with myeloma cells for the monoclonal antibodies.
  • His p53 cf. German patent application P 42 32 823.3
  • the above-obtained monoclonal antibodies may be used as a basis.
  • the necessary portions may then be modified and the non-necessary portions can be fully or partially eliminated and replaced by portions giving the antibodies further favorable properties, respectively.
  • portions can be modified, eliminated or replaced beyond the binding regions of the antibodies.
  • a person skilled in the art knows that particularly the DNA recombination technology is suitable for the above measures. He is perfectly familiar therewith.
  • Antibodies according to the invention distinguish themselves in that they recognize any fusion polypeptides comprising a histidine portion. Therefore, the antibodies are suitable for the rapid detection of the expression of such fusion polypeptides. This may be carried out in any detection methods, particularly in a Western blot, an ELISA, an immunoprecipitation or an immunofluorescence. For this purpose, the antibodies according to the invention may be labeled, if appropriate, or used in combination with labeled antibodies directed thereagainst.
  • mice were used for immunization. His hdm2 (amino acid 1-284), His hdm2 (amino acid 58-491) and His p53 (amino acid 66-393) (cf. above) were used as antigens. They were dissolved in a buffer comprising 8 M urea, 100 mM, NaH 2 PO 4, 10 mM Tris-HCl.
  • the mouse was killed on day 262. Spleen cells were removed therefrom and fused with myeloma cells. Monoclonal antibodies were obtained. One of them was deposited under ACC 2207 with DSM on Feb. 15, 1995.
  • Example 1 The antigens of Example 1 were employed. The immunization and booster pattern was identical with that of Example 1 up to day 90 inclusive.
  • Day 92 5 ml of blood were removed from the rabbit's auricular vein and tested for antibody activity in an ELISA and Western blot, respectively.
  • Day 93 Following a positive test on day 92, the animals were killed and the antibodies were obtained from the serum.
  • the antibody ACC 2207 according to the invention recognizes specifically histidine fusion polypeptides but not polypeptides without histidine portion.
  • a 96-well plate was provided per well with 100 ⁇ l each, which included 20 ng and 8 ng, respectively, of the histidine fusion polypeptides and the controls of (a), respectively. After incubation at 4° C. overnight, 3 short wash steps using PBS followed. Thereafter, the free binding sites of the polymeric carrier were blocked by one-hour incubation using 1% BSA in PBS at 37° C.
  • the antibody ACC 2207 according to the invention which was diluted in a ratio of 1:10 and 1:50, respectively, was incubated on the plate at 37° C. for 1 hour. After 8 wash steps using PBS, the peroxidase-coupled goat anti-mouse antibody of (a) was added.
  • the antibody ACC 2207 according to the invention recognizes specifically histidine fusion polypeptides but not a polypeptide without histidine portion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.

Description

  • The present invention relates to antibodies which are active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and their use. [0001]
  • It is known to express a polypeptide in the form of a histidine fusion polypeptide. In such a polypeptide, a histidine portion of e.g. 6-18 successive histidine residues is fused to the C or N terminus of the polypeptide. Hence it is possible to isolate the histidine fusion polypeptide by means of a nickel-chelate chromatographic column from the supernatant or cell lysate of the cell expressing it. [0002]
  • However, the above column is expensive. Furthermore, its use costs a lot of time. Therefore, it is not suited for the rapid detection of the expression of a histidine fusion polypeptide. But such a detection is necessary, particularly when it shall be used for screening many cells. [0003]
  • Thus, it is the object of the present invention to provide means by which the expression of a histidine fusion polypeptide can be detected rapidly. [0004]
  • According to the invention this is achieved by an antibody which is directed against a fusion. polypeptide comprising a histidine portion. [0005]
  • Such an antibody may be a polyclonal or monoclonal antibody, a monoclonal antibody being preferred. The antibody may be obtained from any animal or human being, rabbits being preferred for a polyclonal antibody and mice being preferred for a monoclonal antibody. [0006]
  • In addition, the antibody may be synthetic, portions which are not necessary for the above-mentioned identification optionally lacking fully or partially therefrom and these portions being replaced by others which give the antibody further favorable properties, respectively. [0007]
  • The expression “fusion polypeptide comprising a histidine portion” comprises a polypeptide (peptide) of any kind and length which has a histidine portion. Such a polypeptide may be expressed by any cells, e.g. bacteria, yeasts, cells of insects, plants and animals, as well as organisms, e.g. transgenic animals. An above histidine portion may comprise e.g. 6-18, preferably 6, successive histidine residues and be fused to the N and/or C terminus of the polypeptide. [0008]
  • A preferred antibody of the present invention, namely a monoclonal mouse antibody having the above identification, was deposited under No. ACC 2207 with the DSM [German-type collection of microorganisms] on Feb. 15, 1995. [0009]
  • Antibodies according to the invention can be prepared according to conventional methods. If polyclonal antibodies and monoclonal antibodies, respectively, are to be prepared, it will be favorable to immunize animals, particularly rabbits for the former antibodies and mice for the latter antibodies, with an above histidine fusion polypeptide e.g. His p53 (cf. German patent application P 42 32 823.3) or His hdm2 (cf. German patent application P 43 39 553.3), preferably a mixture thereof. The animals can be further boostered with the same histidine fusion polypeptide or polypeptides. Other histidine fusion polypeptides or a combination of these and the preceding histidine fusion polypeptide or polypeptides may also be used for boostering. The polyclonal antibodies may then be obtained from the serum of the animals. Spleen cells of the animals are fused with myeloma cells for the monoclonal antibodies. [0010]
  • For the preparation of synthetic antibodies, e.g. the above-obtained monoclonal antibodies may be used as a basis. For this purpose, it is the obvious thing to analyze the antigen-binding region of the monoclonal antibodies and identify the portions which are necessary and not necessary for the above identification. The necessary portions may then be modified and the non-necessary portions can be fully or partially eliminated and replaced by portions giving the antibodies further favorable properties, respectively. Also, portions can be modified, eliminated or replaced beyond the binding regions of the antibodies. A person skilled in the art knows that particularly the DNA recombination technology is suitable for the above measures. He is perfectly familiar therewith. [0011]
  • Antibodies according to the invention distinguish themselves in that they recognize any fusion polypeptides comprising a histidine portion. Therefore, the antibodies are suitable for the rapid detection of the expression of such fusion polypeptides. This may be carried out in any detection methods, particularly in a Western blot, an ELISA, an immunoprecipitation or an immunofluorescence. For this purpose, the antibodies according to the invention may be labeled, if appropriate, or used in combination with labeled antibodies directed thereagainst. [0012]
  • The present invention is explained by the below examples.[0013]
    • EXAMPLE 1 Preparation of Monoclonal Antibodies
  • Mice were used for immunization. His hdm2 (amino acid 1-284), His hdm2 (amino acid 58-491) and His p53 (amino acid 66-393) (cf. above) were used as antigens. They were dissolved in a buffer comprising 8 M urea, 100 mM, NaH[0014] 2PO4, 10 mM Tris-HCl.
  • Immunization and Booster Pattern [0015]
    Day 1: 50 μl (= 10 μg) His hdm2 (amino acid 1-284)
    50 μl (= 10 μg) His hdm2 (amino acid 58-491)
    50 μl PBS (phosphate-buffered saline)
    150 μl Freund's adjuvant complete
    300 μl mix
    200 μl of the mix were injected into a mouse
    Day 30: 50 μl (= 10 μg) His hdm2 (amino acid 1-284)
    50 μl (= 10 μg) His hdm2 (amino acid 58-491)
    20 μl PBS
    120 μl Freund's adjuvant incomplete
    240 μl mix
    200 μl of the mix were injected into the above
    mouse.
    Day 60: 50 μl (= 10 μg) His hdm2 (amino acid 1-284)
    50 μl (= 10 μg) His hdm2 (amino acid 58-491)
    85 μl PBS
    115 μl Freund's adjuvant incomplete
    300 μl mix
    200 μl of the mix were injected into the above
    mouse.
    Day 90: 50 μl (= 10 μg) His hdm2 (amino acid 1-284)
    50 μl (= 10 μg) His hdm2 (amino acid 58-491)
    200 μl PBS
    300 μl mix
    200 μl of the mix were injected into the above
    mouse.
    Day 180: 150 μl (= 20 μg) His p53 (amino acid 66-393)
    150 μl Freund's adjuvant complete
    300 μl mix
    200 μl of the mix were injected into the above
    mouse.
    Day 230: 75 μl (= 10 μg) His p53 (amino acid 66-393)
    25 μl (= 5 μg) His hdm2 (amino acid 1-284)
    25 μl (= 5 μg) His hdm2 (amino acid 58-491)
    125 μl Freund's adjuvant incomplete
    250 μl mix
    200 μl of the mix were injected into the above
    mouse.
    Day 260: 75 μl (= 10 μg) His p53 (amino acid 66-393)
    25 μl (= 5 μg) His hdm2 (amino acid 1-284)
    25 μl (= 5 μg) His hdm2 (amino acid 58-491)
    125 μl PBS
    250 μl mix
    200 ml of the mix were injected into the above
    mouse.
  • The mouse was killed on day 262. Spleen cells were removed therefrom and fused with myeloma cells. Monoclonal antibodies were obtained. One of them was deposited under ACC 2207 with DSM on Feb. 15, 1995. [0016]
  • Preparation of Polyclonal Antibodies [0017]
  • Rabbits were used for immunization. The antigens of Example 1 were employed. The immunization and booster pattern was identical with that of Example 1 up to day 90 inclusive. [0018]
    Day 92: 5 ml of blood were removed from the rabbit's
    auricular vein and tested for antibody activity
    in an ELISA and Western blot, respectively.
    Day 93: Following a positive test on day 92, the animals
    were killed and the antibodies were obtained from
    the serum.
    • EXAMPLE 3 Detection of Histidine Fusion Polypeptides by Antibodies According to the Invention
  • (a) Western Blot [0019]
  • Histidine fusion polypeptides, namely His hdm2 (amino acid 1-284), His hdm2 (amino acid 58-491) and His p53 (amino acid 66-393) of Example 1, as well as the polypeptides hdm2 (amino acid 1-284), WAF 1 (=wild type-activating factor) and t16 (=cell-regulating protein) as control were subjected to a polyacrylamide gel eletrophoresis. The gel was transferred overnight to a nitrocellulose membrane. It was then incubated with the above antibody ACC 2207 diluted in a ratio of 1:10 and 1:50, respectively, at 37° C. for 1 hour. After several wash steps using PBS (0.05% Tween 20), a purchasable alkaline phosphatase-coupled goat-anti-mouse antibody (dilution according to the manufacturer's indication) was added. A 30-minute incubation at 37° C. was followed by several wash steps using PBS and thereafter the alkaline phosphatase detection reaction with alkaline phosphatase including developing solution (36 μM 5′-bromo-4-chloro-3-indolylphosphate, 400 μM nitroblue tetrazolium, 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl[0020] 2) at room temperature until bands were visible.
  • It showed that the antibody ACC 2207 according to the invention recognizes specifically histidine fusion polypeptides but not polypeptides without histidine portion. [0021]
  • (b) ELISA [0022]
  • A 96-well plate was provided per well with 100 μl each, which included 20 ng and 8 ng, respectively, of the histidine fusion polypeptides and the controls of (a), respectively. After incubation at 4° C. overnight, 3 short wash steps using PBS followed. Thereafter, the free binding sites of the polymeric carrier were blocked by one-hour incubation using 1% BSA in PBS at 37° C. The antibody ACC 2207 according to the invention which was diluted in a ratio of 1:10 and 1:50, respectively, was incubated on the plate at 37° C. for 1 hour. After 8 wash steps using PBS, the peroxidase-coupled goat anti-mouse antibody of (a) was added. A 30-minute incubation at 37° C. was followed by 8 wash steps and thereafter the peroxidase detection reaction with developing solution (50 mM sodium acetate, 0.4 mM 3,3′,5,5′-tetramethylbenzidine dihydrochloride, 4.4 mM H[0023] 2O2) at room temperature until bands were visible.
  • It showed that the antibody ACC 2207 according to the invention recognizes specifically histidine fusion polypeptides but not a polypeptide without histidine portion. [0024]

Claims (8)

1. An antibody against a fusion polypeptide comprising a histidine portion.
2. The antibody according to claim 1, characterized in that it is polyclonal.
3. The antibody according to claim 1, characterized in that it is monoclonal.
4. The antibody according to claim 3, characterized in that it is deposited under ACC 2207 with DSM [German-type culture collection for microorganisms].
5. A process for the preparation of an antibody according to any one of claims 1 to 4, characterized in that an animal is immunized with a histidine fusion polypeptide and
(a) polyclonal antibodies are obtained from the serum of the animal, or
(b) monoclonal antibodies are obtained after the fusion of animals spleen cells with myeloma cells.
6. The process according to claim 5, characterized in that a mixture of histidine fusion polypeptides is used for immunization.
7. Use of an antibody according to any one of claims 1 to 4 in a detection method for a fusion polypeptide comprising a histidine portion.
8. Use according to claim 7, wherein the detection method is a Western blot, an ELISA, an immunofluorescence or an immunoprecipitation.
US10/686,355 1995-03-01 2003-10-14 Antibodies active against a fusion polypeptide comprising a histidine portion Abandoned US20040105854A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/686,355 US20040105854A1 (en) 1995-03-01 2003-10-14 Antibodies active against a fusion polypeptide comprising a histidine portion
US12/465,855 US7713712B2 (en) 1995-03-01 2009-05-14 Antibodies active against a fusion polypeptide comprising a histidine portion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19507166.2 1995-03-01
DE19507166A DE19507166C1 (en) 1995-03-01 1995-03-01 Antibodies specific for fusion polypeptide(s) contg. a histidine component
US08/913,139 US6790940B1 (en) 1995-03-01 1996-03-01 Antibodies active against a fusion polypeptide comprising a histidine portion
US10/686,355 US20040105854A1 (en) 1995-03-01 2003-10-14 Antibodies active against a fusion polypeptide comprising a histidine portion

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US08913139 Continuation 1996-03-01
PCT/DE1996/000369 Continuation WO1996026963A1 (en) 1995-03-01 1996-03-01 Antibodies active against a fusion polypeptide comprising a histidine portion
US08/913,139 Continuation US6790940B1 (en) 1995-03-01 1996-03-01 Antibodies active against a fusion polypeptide comprising a histidine portion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/465,855 Continuation US7713712B2 (en) 1995-03-01 2009-05-14 Antibodies active against a fusion polypeptide comprising a histidine portion

Publications (1)

Publication Number Publication Date
US20040105854A1 true US20040105854A1 (en) 2004-06-03

Family

ID=7755368

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/913,139 Expired - Lifetime US6790940B1 (en) 1995-03-01 1996-03-01 Antibodies active against a fusion polypeptide comprising a histidine portion
US10/686,355 Abandoned US20040105854A1 (en) 1995-03-01 2003-10-14 Antibodies active against a fusion polypeptide comprising a histidine portion
US12/465,855 Expired - Fee Related US7713712B2 (en) 1995-03-01 2009-05-14 Antibodies active against a fusion polypeptide comprising a histidine portion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/913,139 Expired - Lifetime US6790940B1 (en) 1995-03-01 1996-03-01 Antibodies active against a fusion polypeptide comprising a histidine portion

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/465,855 Expired - Fee Related US7713712B2 (en) 1995-03-01 2009-05-14 Antibodies active against a fusion polypeptide comprising a histidine portion

Country Status (9)

Country Link
US (3) US6790940B1 (en)
EP (1) EP0815141B2 (en)
JP (1) JP3799059B2 (en)
AT (1) ATE207935T1 (en)
CA (1) CA2217186A1 (en)
DE (2) DE19507166C1 (en)
DK (1) DK0815141T3 (en)
ES (1) ES2166878T3 (en)
WO (1) WO1996026963A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19507166C1 (en) 1995-03-01 1996-04-18 Deutsches Krebsforsch Antibodies specific for fusion polypeptide(s) contg. a histidine component
DE19728697C1 (en) * 1997-07-04 1999-03-25 Deutsches Krebsforsch Human antibody against a fusion (poly) peptide or protein which contains at least six histidines
US7794946B1 (en) 1998-02-04 2010-09-14 Life Technologies Corporation Microarray and uses therefor
DE69922365T2 (en) * 1998-04-30 2005-04-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. NEW METHOD FOR SELECTION OF CLONES OF AN EXPRESSION LIBRARY BY REARRAYING
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
EP1587907B1 (en) 2003-01-07 2011-03-02 Dyax Corporation Kunitz domain library
SG187787A1 (en) 2010-08-10 2013-03-28 Amgen Inc Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
JP5849275B2 (en) * 2011-07-11 2016-01-27 国立大学法人山口大学 Anti-histidine tag antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790940B1 (en) * 1995-03-01 2004-09-14 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Antibodies active against a fusion polypeptide comprising a histidine portion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130416A (en) 1986-08-13 1992-07-14 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA clone containing a genomic fragment of PfHRP-II gene from plasmodium falciparum
JPH07501711A (en) * 1992-09-30 1995-02-23 ドイチェス　クレブスフォーシュングスツェントラム　スチフトゥング　デス　エフェントリヒェン　レヒツ Detection method for p53-specific antibodies
DE4339533C2 (en) * 1993-11-19 1997-07-03 Deutsches Krebsforsch Detection method for hdm-2 specific antibodies
US5840834A (en) * 1994-12-21 1998-11-24 Virginia Commonwealth University Technique for joining amino acid sequences and novel composition useful in immunoassays

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790940B1 (en) * 1995-03-01 2004-09-14 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Antibodies active against a fusion polypeptide comprising a histidine portion

Also Published As

Publication number Publication date
EP0815141A1 (en) 1998-01-07
EP0815141B1 (en) 2001-10-31
DE19507166C1 (en) 1996-04-18
US20090221040A1 (en) 2009-09-03
ATE207935T1 (en) 2001-11-15
JP3799059B2 (en) 2006-07-19
JPH11510785A (en) 1999-09-21
US6790940B1 (en) 2004-09-14
DK0815141T3 (en) 2002-01-21
CA2217186A1 (en) 1996-09-06
WO1996026963A1 (en) 1996-09-06
ES2166878T3 (en) 2002-05-01
US7713712B2 (en) 2010-05-11
DE59608073D1 (en) 2001-12-06
EP0815141B2 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
US7713712B2 (en) Antibodies active against a fusion polypeptide comprising a histidine portion
EP1881064B1 (en) HCV-Anti-core monoclonal antibody
US6808901B1 (en) Production of chimeric antibodies
CN112626089A (en) SARS-CoV-2 virus S protein receptor binding region coding gene, antibody and application
CA2868161A1 (en) Anti-hcmv idiotypic antibodies and uses thereof
KR19990067153A (en) Monoclonal Antibodies Specific to Prostaglandin Di Synthase
KR101263913B1 (en) Bovine tuberculosis diagnosing kit and diagnosing method using the same
EP0401370B1 (en) Enzyme immunoassay according to sandwich method of human iv-type collagen
CN116284352A (en) Bovine leukemia virus antibody and detection kit
Bolwell et al. Demonstration of a common antigenic site on endomembrane proteins of Phaseolus vulgaris by a rat monoclonal antibody: tentative identification of arabinan synthase and consequences for its regulation
Mather et al. Preparation of monoclonal antibodies to xanthine oxidase and other proteins of bovine milk-fat-globule membrane.
US5665559A (en) Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D
JP3018451B2 (en) Antibodies against highly conserved amino acid sequences of immunogens, methods for producing these antibodies and their use in immunoassays
IE63371B1 (en) Monoclonal antibodies for the selective immunological determination of intact procollagen peptide (Type III) and procollagen (Type III) in body fluids
Hohmann et al. Monoclonal alkaline phosphatase-anti-alkaline phosphatase (APAAP) complex: production of antibody, optimization of activity, and use in immunostaining.
US8349569B2 (en) Anti-fibronectin fragment monoclonal antibody
US5972633A (en) Antibodies against heart muscle actin
EP0312645B1 (en) Antigenic peptides from complement factor c3a, use of peptides, cell lines, antibodies against the peptides and utilisation of the antibodies
JPH0746105B2 (en) Immunochemical assay method for interferon-γ and reagent for assay
KR930701619A (en) Monoclonal antibody against gag protein precursor p55 of human immunodeficiency virus
JP3522877B2 (en) Anti-tyrosinase monoclonal antibody F (ab ') 2 fragment
Bröker et al. Defined monoclonal antibodies to Escherichia coli β-galactosidase as a tool for characterisation of recombinant expression products
KR20210131045A (en) Pine wood nematode secretory antigen PWN-SA571 specific antibodies and uses thereof
KR20210116113A (en) c-Myc peptide specific antibody and uses thereof
Hohmann et al. Mouse monoclonal anti-idiotypic antibodies to HIV p24: Immunochemical properties and internal imagery

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION